x

VTU Technology is now VALIDOGEN

News Übersicht
VTU Technology is now VALIDOGEN 22.10.2018

PRESS RELEASE

Change of Company Name: VTU Technology is now VALIDOGEN

UNLOCK PICHIA – A technology from VALIDOGEN

Raaba-Grambach, Austria – October 22, 2018

VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.

Founded in 2008, VTU Technology has become a recognized player in the field of Pichia pastoris based protein production and will now continue its business as VALIDOGEN, a private company and independent subsidiary of KonValue Group.

„VALIDOGEN will continue to be a leading partner for the development of microbial protein production strains and processes“, said Dr. Michael Koncar, founder and CEO of VALIDOGEN and KonValue Group.


UNLOCK PICHIA – a technology from VALIDOGEN

In connection with the company’s name change, VALIDOGEN introduces UNLOCK PICHIA as a label for its established, exclusive Pichia protein production technology. UNLOCK PICHIA is known as the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production.
The company has been continuously working on the optimization and expansion of its Pichia toolbox, which is unmatched in terms of genetic diversity. UNLOCK PICHIA addresses challenges all the way from transcription and translation to translocation, protein folding and secretion and facilitates the expression of more complex proteins thus maximizing yields without compromising product quality.


About VALIDOGEN GmbH

VALIDOGEN, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production known as UNLOCK PICHIA. VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailor-made solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries. VALIDOGEN will be a private company and independent subsidiary of KonValue Group.
More Information: www.validogen.com, www.unlockpichia.com


Contact: VALIDOGEN GmbH
Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18, A-8074 Raaba-Grambach
Tel: +43 316 4009 4017
E-Mail: thomas.purkarthofer@validogen.com

X
KEEP in TOUCH
Sign up to our mailing list to keep up with latest developments and information around Pichia based protein expression.
Yes, I agree with the regular receipt of the VALIDOGEN newsletter. The subscription to the newsletter can be canceled at any time
(see privacy policy)
GET in TOUCH
X
Welcome to VALIDOGEN!
Would you like us to contact you personally?
REQUEST NOW

News

VALIDOGEN to present at PICHIA 2021, online conference, March 24 - April 1

Pichia 2021, online conference "Don't miss latest insights into UNLOCK ...
Details

New case study on VHH antibody expression underlines the power of UNLOCK PICHIA

We conducted a series of case studies, demonstrating the yield-enhancing ...
Details

Downloads

Company folder and brochures

All downloads
Tablet Potrait-Mode gerade in Arbeit, bitte drehen Sie das Tablet in den Landscape-Mode.